Portal de Periódicos da CAPES

Farnesyltransferase inhibitors: promises and realities

2002; Elsevier BV; Volume: 2; Issue: 4 Linguagem: Inglês

10.1016/s1471-4892(02)00181-9

1471-4973

Adrienne D. Cox, Channing J. Der,

Cancer-related Molecular Pathways

Farnesyltransferase inhibitors have recently shown clinical efficacy against leukemias, gliomas and even non-small-cell lung cancers, especially when administered in combination with taxanes. It is possible that the critical target downstream of farnesyltransferase responsible for these effects is not either Ras or RhoB, the two most cited possibilities — but the hunt is on.